Philip Kowalczyk - LivaNova PLC Chief Officer

LIVN Stock  USD 51.50  0.61  1.17%   

Executive

Philip Kowalczyk is Chief Officer of LivaNova PLC
Address 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
Phone44 20 3325 0660
Webhttps://www.livanova.com

LivaNova PLC Management Efficiency

The company has return on total asset (ROA) of 0.0434 % which means that it generated a profit of $0.0434 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0187 %, meaning that it created $0.0187 on every $100 dollars invested by stockholders. LivaNova PLC's management efficiency ratios could be used to measure how well LivaNova PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, LivaNova PLC's Return On Tangible Assets are very stable compared to the past year. As of the 16th of December 2024, Return On Assets is likely to grow to 0.01, while Return On Capital Employed is likely to drop (0.03). At this time, LivaNova PLC's Intangible Assets are very stable compared to the past year. As of the 16th of December 2024, Net Tangible Assets is likely to grow to about 116.1 M, while Deferred Long Term Asset Charges is likely to drop about 4.8 M.
LivaNova PLC currently holds 640.4 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. LivaNova PLC has a current ratio of 2.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about LivaNova PLC's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Jennifer BoyerInogen Inc
N/A
Donna ShiromaAvita Medical
61
Taylor EricksonTreace Medical Concepts
N/A
Aaron BeruttiTreace Medical Concepts
45
David OTooleAvita Medical
65
Paul AndreassiInogen Inc
N/A
Scot ElderTreace Medical Concepts
49
Sean ScanlanTreace Medical Concepts
42
Kevin SmithInogen Inc
53
Philip CorrinInogen Inc
N/A
Jessica EkebergAvita Medical
N/A
Vijay PaliwalInogen Inc
N/A
Katie BushAvita Medical
N/A
Julie DeweyTreace Medical Concepts
63
Nathan MinnichTreace Medical Concepts
N/A
Scot JDTreace Medical Concepts
49
Matthew CPAApyx Medical
55
Shana ZinkTreace Medical Concepts
N/A
Debbie GarnerAvita Medical
N/A
Adrien MithalalInogen Inc
N/A
Rob HallAvita Medical
N/A
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. Livanova Plc operates under Medical Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. LivaNova PLC (LIVN) is traded on NASDAQ Exchange in USA. It is located in 20 Eastbourne Terrace, London, United Kingdom, W2 6LG and employs 2,900 people. LivaNova PLC is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

LivaNova PLC Leadership Team

Elected by the shareholders, the LivaNova PLC's board of directors comprises two types of representatives: LivaNova PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LivaNova. The board's role is to monitor LivaNova PLC's management team and ensure that shareholders' interests are well served. LivaNova PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LivaNova PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lindsey Little, Director Relations
Damien McDonald, CEO Director
Philip Kowalczyk, Chief Officer
Alex CMA, Chief Officer
William Kozy, Chairman CEO
Stephanie Bolton, President Epilepsy
Matthew III, Senior IT
Badri Amurthur, Chief Officer
Trui Hebbelinck, Chief Human Resource Officer
Deanna Wilke, Vice Communications
Paul Buckman, President Replacement
John Webb, Vice Epilepsy
Keyna Skeffington, Senior Vice President General Counsel
Michael Hutchinson, Chief VP
Ryan Miller, President Support
Alex Shvartsburg, Chief Officer
Ahmet Tezel, Chief Officer
Bryan Olin, Senior Neuromodulation
Vladimir Makatsaria, CEO Director
Marco Dolci, Pres Unit
Jonathan Walker, VP Segment
Franco Poletti, President Unit

LivaNova Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LivaNova PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with LivaNova PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if LivaNova PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LivaNova PLC will appreciate offsetting losses from the drop in the long position's value.

Moving against LivaNova Stock

  0.39VVOS Vivos TherapeuticsPairCorr
  0.37GH Guardant HealthPairCorr
The ability to find closely correlated positions to LivaNova PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace LivaNova PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back LivaNova PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling LivaNova PLC to buy it.
The correlation of LivaNova PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as LivaNova PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if LivaNova PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for LivaNova PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether LivaNova PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of LivaNova PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Livanova Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Livanova Plc Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
14
Earnings Share
0.43
Revenue Per Share
22.907
Quarterly Revenue Growth
0.112
Return On Assets
0.0434
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.